BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann M.D., Ph.D., President and CEO, will participate in two panel discussions on addiction and digital therapeutics at the 2019 HLTH Conference being held October 27- 30 at the MGM Grand Convention Center in Las Vegas. Details for the panel discussions are below:
- Slaying Addiction on Monday, October 28 at 2:00 p.m. Pacific Time
- Going Beyond Behavioral Health to New Modalities on Wednesday, October 30 at 12:00 p.m. Pacific Time
Pear Therapeutics is a privately held, prescription digital therapeutics company developing clinically validated, FDA-authorized software applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, for the treatment of Substance Use Disorder, was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at www.peartherapeutics.com.